To screen for the potential biomarkers specifically linked to the anti-PD-L1 therapy efficacy, we collected the serum of three patients with ESCC with progressive disease (PD) and three patients with ESCC who achieved partial response (PR) after two cycles of anti-PD-L1 immunotherapy for human circular RNA array. The gene discussed is CD274; the disease is esophageal squamous cell carcinoma.